Highlights Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-27 EDT			5-day change	1st Jan Change
0.7152 ^USD	+1.95%		+10.03%	-31.89%

06-26	Transcript : Quince Therapeutics, Inc. - Special Call
06-25	Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia	06-25	MT
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of Erydex for the Treatment of Ataxia-Telangiectasia	06-25	CI
Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System	06-03	CI
Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Quince Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Quince Therapeutics, Inc. acquired EryDel S.p.A	23-10-22	CI
Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug Application for Its Lead Phase 3 Asset, Erydex	23-09-28	CI
Quince Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Quince Therapeutics to Acquire EryDel in All-Stock Deal	23-07-24	MT
Quince Therapeutics, Inc. agreed to acquire EryDel S.p.A. for approximately $510 million.	23-07-23	CI
Quince Therapeutics Shares Rise Pre-Bell After Echo Lake Capital Raises Acquisition Offer	23-07-13	MT
Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Biomed Industries, Inc. submitted a proposal to acquire Quince Therapeutics, Inc. for $94 million.	23-05-02	CI
Quince Therapeutics Rejects Acquisition Proposal From Echo Lake Capital	23-04-11	MT
Echo Lake Capital cancelled the acquisition of Quince Therapeutics, Inc..	23-04-10	CI
Quince Therapeutics Engages MTS Heath Partners to Review Strategic Alternatives	23-04-06	CI
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan; Sets Dividend Distribution	23-04-05	MT
Fed Rate Announcement Eyed as Exchange-Traded Funds, Equity Futures Mixed Premarket Wednesday	23-03-22	MT
Quince Therapeutics Confirms Echo Lake Capital Offer; Says to 'Carefully' Review Proposal	23-03-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Highlights

Filters